NEW YORK (GenomeWeb) – Biotech firm Berg announced today that it has partnered with Sanofi to identify biomarkers of influenza vaccine performance.
Under the terms of the deal, Berg will use its Interrogative Biology platform — which uses the company's artificial intelligence technology to analyze molecular and clinical data — in order to assess potential biomarkers of seasonal influenza vaccination outcomes in an unbiased and data-driven manner.
Additional terms were not disclosed.
"Interrogative Biology includes multi-omic profiling of samples from individuals participating in a longitudinal study with Sanofi Pasteur-licensed vaccines and subsequent use of our bAIcis artificial intelligence tool with the aim to identify molecular signatures and potential biomarkers indicative of breadth and durability of the influenza vaccine immunological response," Berg Cofounder, President, and CEO Niven Narain said in a statement.